Opinion|Videos|August 7, 2024
Efficacy and Safety of Subcutaneous Infliximab
Author(s)Jean-Frederic Colombel, MD
A key opinion leader analyzes the clinical remission and endoscopic response data from the LIBERTY CD and LIBERTY UC trials for subcutaneous infliximab-dyyb injection, contrasts it with intravenous infliximab, and evaluates the drug's safety and efficacy profile.
Advertisement
- What are the key findings regarding the clinical remission and endoscopic response of subcutaneous infliximab-dyyb injection from the LIBERTY CD and LIBERTY UC trials?
- How does subcutaneous infliximab injection compare to IV infliximab in terms of sustenance of drug levels?
- Are there any clinical advantages of the subcutaneous delivery over the IV route?
- How does the safety profile of subcutaneous infliximab injection compare to IV infliximab?
Advertisement
Related to this article
Iliyan D. Iliev, PhD, discusses how fluconazole targets gut Candida to improve disease activity in IBD.
Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
Agusti, chair of the GOLD Board of Directors, discusses which COPD diagnostic bottleneck AI is closest to solving and more.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
Advertisement
Advertisement
Trending on HCPLive
1
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
2
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
3
Targeting Gut Candida to Treat IBD, With Iliyan D. Iliev, PhD
4
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
5